Posted on

Cannabinoid type 2 (CB2) receptor system modulates paclitaxel-induced microglial dysregulation and central sensitization in rats

Chemotherapy-induced peripheral neuropathy (CIPN) occurs in 40 to 60% of patients who receive paclitaxel, which is used clinically to treat breast, lung, and ovarian cancer.12,44 CIPN appears to be a dose-limiting toxicity, especially after multiple treatment courses.49 CIPN may also persist for years after the therapy is stopped; a small percentage of patients experience life-long CIPN.15

Cannabinoid type 2 (CB2) receptor system modulates paclitaxel-induced microglial dysregulation and central sensitization in rats

Orginally Published At: Pain Journal

Leave a Reply

Your email address will not be published. Required fields are marked *